{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79"}]}],"title":"Any TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Any TESAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"An Adverse Event (AE) is any unfavourable and unintended sign, symptoms, or diseases temporally associated with use of study drug, whether or not considered related to study drug. A serious adverse event (SAE) is an AE that results in death, initial or prolonged inpatient hospitalization, life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or an important medical event. TEAEs and TESAEs are defined as AEs and SAEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug.","groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"OG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population included participants who received at least 1 dose of moxetumomab pasudotox.","reportingStatus":"POSTED","timeFrame":"From the start of study treatment (Day 1) through 4-6 weeks after last dose of Cycle 6 (28-day cycle) (approximately 7 months)","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}